Evolution of adjuvants across the centuries

Vaccines: Sixth Edition

Volumn , Issue , 2012, Pages 58-70

  Garçon, Nathalie ^a   Hem, Stanley ^c   Friede, Martin ^b  

^a GSK   (Belgium)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902048577     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0090-5.00020-3     Document Type: Chapter

References (152)

1. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
2. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9:287-293.
3. Minutello M., Senatore F., Cecchinelli G., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999, 17:99-104.
4. Morel S., Didierlaurent A., Bourguignon P., et al. Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
5. Paavonen J., Naud P., Salmeron J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
6. Klinman DM., Currie D., Gursel I., et al. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004, 199:201-216.
7. Cohen J., Benns S., Vekemans J., et al. malaria vaccine candidate RTS,S/AS is in phase III clinical trials [in French]. Ann Pharm Fr 2010, 68:370-379.
8. Garçon N., Segal L., Tavares F., et al. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 2011, 29:4453-4459.
9. Ramon G. Sur l'augmentation anormale de l'antitoxine chez les chevaux producteurs de sérum antidiphtérique. Bull Soc Centr Med Vet 1925, 101:227-234.
10. Glenny A., Pope C., Waddington H. The antigenic value of toxoid precipitated by potassium alum. J Pathol Bacteriol 1926, 29:31-40.
11. Lemaitre B., Nicolas E., Michaut L., et al. The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 1996, 86:973-983.
12. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997 Jul 24, 388(6640):394-397.
13. Poltorak A., He X., Smirnova I., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998, 282:2085-2088.
14. Janeway C.A., Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002, 20:197-216.
15. Tomai M.A., Solem L.E., Johnson A.G., Ribi E. The adjuvant properties of a nontoxic monophosphoryl lipid A in hyporesponsive and aging mice. J Biol Response Mod 1987 Ap, 6(2):99-107.
16. Onomoto K., Yoneyama M., Fujita T. Regulation of antiviral innate immune responses by RIG-I family of RNA helicases. Curr Top Microbiol Immunol 2007, 316:193-205.
17. Carneiro L.A., Travassos L.H., Girardin S.E. NOD-like receptors in innate immunity and inflammatory diseases. Ann Med 2007, 39:581-593.
18. Martinon F., Tschopp J. NLRs join TLRs as innate sensors of pathogens. Trends Immunol 2005, 26:447-454.
19. Palsson-McDermott E.M., O'Neill L.A. Building an immune system from nine domains. Biochem Soc Trans 2007, 35(pt 6):1437-1444.
20. Redecke V., Hacker H., Datta S.K., et al. Cutting edge: activation of Toll-like receptor 2 induces a Th2 immune response and promotes experimental asthma. J Immunol 2004, 172:2739-2743.
21. Shirodkar S., Hutchinson R.L., Perry D.L., et al. Aluminum compounds used as adjuvants in vaccines. Pharm Res 1990, 7:1282-1288.
22. Johnston C.T., Wang S.L., Hem S.L. Measuring the surface area of aluminum hydroxide adjuvant. J Pharm Sci 2002, 91:1702-1706.
23. Liu J.C., Feldkamp J.R., White J.L. Adsorption of phosphate by aluminum hydroxycarbonate. J Pharm Sci 1984, 73:1355-1358.
24. Hem K.J., Dandashli E.A., White J.L., et al. Accessibility of antigen in vaccines produced by in situ alum precipitation. Vaccine Res 1996, 5:189-191.
25. White J.L., Hem S.L. Characterization of aluminum-containing adjuvants. Physico-Chemical Procedures for the Characterization of Vaccines 2000, 217-228. Karger, Basel, Switzerland. F. Brown, M. Corbel, E. Griffiths (Eds.).
26. Galazka A., Milstein J., Zaffran M. Thermostability of vaccines 1998, World Health Organization, Geneva, Switzerland.
27. Seeber S.J., White J.L., Hem S.L. Predicting the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1991, 9:201-203.
28. Chang M.F., White J.L., Nail S.L., et al. Role of the electrostatic attractive force in the adsorption of proteins by aluminum hydroxide adjuvant. PDA J Pharm Sci Technol 1997, 51:25-29.
29. al-Shakhshir R.H., Regnier F.E., White J.L., et al. Contribution of electrostatic and hydrophobic interactions to the adsorption of proteins by aluminium-containing adjuvants. Vaccine 1995, 13:41-44.
30. Gupta R.K., Rost B.E., Relyveld E., et al. Adjuvant properties of aluminum and calcium compounds. Pharm Biotechnol 1995, 6:229-248.
31. Marrack P., McKee A.S., Munks M.W. Towards an understanding of the adjuvant action of aluminium. Nat Rev Immunol 2009, 9:287-293.
32. Morefield G.L., Sokolovska A., Jiang D., et al. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine 2005, 23:1588-1595.
33. Eisenbarth S.C., Colegio O.R., O'Connor W., et al. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature 2008, 453:1122-1126.
34. Kool M., Petrilli V., De Smedt T., et al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J Immunol 2008, 181:3755-3759.
35. Flach T.L., Ng G., Hari A., et al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat Med 2011, 17:479-487.
36. Gherardi R.K., Coquet M., Cherin P., et al. Macrophagic myofasciitis lesions assess long-term persistence of vaccine-derived aluminium hydroxide in muscle. Brain 2001, 124(pt 9):1821-1831.
37. Brenner A. Macrophagic myofasciitis: a summary of Dr. Gherardi's presentations. Vaccine 2002, 20(suppl 3):S5-S6.
38. WHO Vaccine Safety Advisory Committee Macrophagic myofasciitis and aluminum-containing vaccines. Wkly Epidemiol Rec 1999, 74:338-340.
39. Baylor N.W., Egan W., Richman P. Aluminum salts in vaccines: US perspective. Vaccine 2002, 20(suppl 3):S18-S23.
40. Salk J.E., Bailey M.L., Laurent A.M. The use of adjuvants in studies on influenza immunization, II: increased antibody formation in human subjects inoculated with influenza virus vaccine in a water in-oil emulsion. Am J Hyg 1952, 55:439-456.
41. Salk J.E., Laurent A.M., Bailey M.L. Direction of research on vaccination against influenza: new studies with immunologic adjuvants. Am J Public Health Nations Health 1951, 41:669-677.
42. Beebe G.W., Simon A.H., Vivona S. Follow-up study on army personnel who received adjuvant influenza virus vaccine 1951-1953. Am J Med Sci 1964, 247:385-406.
43. Page W.F., Norman J.E., Benenson A.S. Long-term follow up of Army recruits immunized with Freund's incomplete adjuvanted vaccine. Vaccine Res 1993, 2:141-149.
44. Murray R., Cohen P., Hardegree M.C. Mineral oil adjuvants: biological and chemical studies. Ann Allergy 1972, 30:146-151.
45. Toledo H., Baly A., Castro O., et al. A phase I clinical trial of a multi-epitope polypeptide TAB9 combined with Montanide ISA 720 adjuvant in non-HIV-1 infected human volunteers. Vaccine 2001, 19:4328-4336.
46. Saul A., Lawrence G., Allworth A., et al. A human phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide ISA720 adjuvant. Vaccine 2005, 23:3076-3083.
47. Allison A.C., Byars N.E. An adjuvant formulation that selectively elicits the formation of antibodies of protective isotypes and of cell-mediated immunity. J Immunol Methods 1986, 95:157-168.
48. Fox C.B., Anderson R.C., Dutill T.S., et al. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf B Biointerfaces 2008, 65:98-105.
49. Minutello M., Senatore F., Cecchinelli G., et al. Safety and immunogenicity of an inactivated subunit influenza virus vaccine combined with MF59 adjuvant emulsion in elderly subjects, immunized for three consecutive influenza seasons. Vaccine 1999, 17:99-104.
50. Treanor J.J., Campbell J.D., Zangwill K.M., et al. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006, 354:1343-1351.
51. Nicholson K.G., Colegate A.E., Podda A., et al. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001, 357:1937-1943.
52. Stoute J.A., Slaoui M., Heppner D.G., et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. RTS,S Malaria Vaccine Evaluation Group. N Engl J Med 1997, 336:86-91.
53. Atmar R.L., Keitel W.A., Patel S.M., et al. Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations. Clin Infect Dis 2006, 43:1135-1142.
54. Fox C.B., Lin S., Sivananthan S.J., et al. Effects of emulsifier concentration, composition, and order of addition in squalene-phosphatidylcholine oil-in-water emulsions. Pharm Dev Technol 2011, 16:511-519.
55. Llanos-Cuentas A., Calderon W., Cruz M., et al. A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine when used in combination with sodium stibogluconate for the treatment of mucosal leishmaniasis. Vaccine 2010, 28:7427-7435.
56. Bodewes R., Kreijtz J.H., van Amerongen G., et al. A single immunization with CoVaccine HT-adjuvanted H5N1 influenza virus vaccine induces protective cellular and humoral immune responses in ferrets. J Virol 2010, 84:7943-7952.
57. Frey S., Poland G., Percell S., et al. Comparison of the safety, tolerability, and immunogenicity of a MF59-adjuvanted influenza vaccine and a non-adjuvanted influenza vaccine in non-elderly adults. Vaccine 2003, 21:4234-4237.
58. Vesikari T., Pellegrini M., Karvonen A., et al. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009, 28:563-571.
59. Vesikari T., Knuf M., Wutzler P., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011 Oct 13, 365(15):1406-1416.
60. De Donato S., Granoff D., Minutello M., et al. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999, 17:3094-3101.
61. Khurana S., Chearwae W., Castellino F., et al. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2010, 2:15ra5.
62. Baras B., Stittelaar K.J., Simon J.H., et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PLoS One 2008, 3:e1401. doi:10.1371/journal.pone.0001401.
63. Leroux-Roels I., Bernhard R., Gérard P., et al. Broad clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS One 2008, 3:e1665. doi:10.1371/journal.pone.0001665.
64. Khurana S., Verma N., Yewdell J.W., et al. Sci Transl Med 2011, 3:85ra48.
65. Mosca F., Tritto E., Muzzi A., et al. Molecular and cellular signatures of human vaccine adjuvants. Proc Natl Acad Sci U S A 2008, 105:10501-10506.
66. Morel S., Didierlaurent A., Bourguignon P., et al. Adjuvant system AS03 containing alpha-tocopherol modulates innate immune response and leads to improved adaptive immunity. Vaccine 2011, 29:2461-2473.
67. Asa P.B., Wilson R.B., Garry R.F. Antibodies to squalene in recipients of anthrax vaccine. Exp Mol Pathol 2002, 73:19-27.
68. Carlson B.C., Jansson A.M., Larsson A., et al. The endogenous adjuvant squalene can induce a chronic T-cell-mediated arthritis in rats. Am J Pathol 2000, 156:2057-2065.
69. Montastruc J.L., Durrieu G., Rascol O. Pandemrix°, (H1N1)v influenza and reported cases of narcolepsy [letter]. Vaccine 2011, 29:2010.
70. Kamimura H., Koga N., Oguri K., et al. Studies on distribution, excretion and subacute toxicity of squalane in dogs [in Japanese]. Fukuoka Igaku Zasshi 1989, 80:269-280.
71. Jansen T., Hofmans M.P., Theelen M.J., et al. Structure- and oil type-based efficacy of emulsion adjuvants. Vaccine 2006, 24:5400-5405.
72. Alving C.R., Verma J.N., Rao M., et al. Liposomes containing lipid A as a potent non-toxic adjuvant. Res Immunol 1992, 143:197-198.
73. Takayama K., Qureshi N., Ribi E., et al. Separation and characterization of toxic and nontoxic forms of lipid A. Rev Infect Dis 1984, 6(4):439-443. Jul-Aug.
74. Descamps D., Hardt K., Spiessens B., et al. Safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine for cervical cancer prevention: a pooled analysis of 11 clinical trials. Hum Vaccin 2009, 5:332-340.
75. Paavonen J., Naud P., Salmeron J., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
76. Miyake K. Roles for accessory molecules in microbial recognition by Toll-like receptors. J Endotoxin Res 2006, 12:195-204.
77. Miyake K., Nagai Y., Akashi S., et al. Essential role of MD-2 in B-cell responses to lipopolysaccharide and Toll-like receptor 4 distribution. J Endotoxin Res 2002, 8:449-452.
78. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801.
79. Barton G.M., Kagan J.C. A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 2009, 9:535-542.
80. Mata-Haro V., Cekic C., Martin M., et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 2007, 316:1628-1632.
81. Hajjar A.M., Ernst R.K., Tsai J.H., et al. Human Toll-like receptor 4 recognizes host-specific LPS modifications. Nat Immunol 2002, 3:354-359.
82. Meraldi V., Audran R., Romero J.F., et al. OM-174, a new adjuvant with a potential for human use, induces a protective response when administered with the synthetic C-terminal fragment 242-310 from the circumsporozoite protein of Plasmodium berghei. Vaccine 2003, 21:2485-2491.
83. Stover A.G., Da Silva C.J., Evans J.T., et al. Structure-activity relationship of synthetic Toll-like receptor 4 agonists. J Biol Chem 2004, 279:4440-4449.
84. Johnson D.A. Synthetic TLR4-active glycolipids as vaccine adjuvants and stand-alone immunotherapeutics. Curr Top Med Chem 2008, 8:64-79.
85. Dupont J., Altclas J., Lepetic A., et al. A controlled clinical trial comparing the safety and immunogenicity of a new adjuvanted hepatitis B vaccine with a standard hepatitis B vaccine. Vaccine 2006, 24:7167-7174.
86. Coler R.N., Bertholet S., Moutaftsi M., et al. Development and characterization of synthetic glucopyranosyl lipid adjuvant system as a vaccine adjuvant. PLoS One 2011, 6:e16333. doi:10.1371/journal.pone.0016333.
87. Ishizaka S.T., Hawkins L.D. E6020: a synthetic Toll-like receptor 4 agonist as a vaccine adjuvant. Expert Rev Vaccines 2007, 6:773-784.
88. Quintilio W., Kubrusly F.S., Iourtov D., et al. Bordetella pertussis monophosphoryl lipid A as adjuvant for inactivated split virion influenza vaccine in mice. Vaccine 2009, 27:4219-4224.
89. Tiberio L., Fletcher L., Eldridge J.H., et al. Host factors impacting the innate response in humans to the candidate adjuvants RC529 and monophosphoryl lipid A. Vaccine 2004, 22:1515-1523.
90. Mueller M., Lindner B., Kusumoto S., et al. Aggregates are the biologically active units of endotoxin. J Biol Chem 2004, 279:26307-26313.
91. Anderson R.C., Fox C.B., Dutill T.S., et al. Physicochemical characterization and biological activity of synthetic TLR4 agonist formulations. Colloids Surf B Biointerfaces 2010, 75:123-132.
92. Didierlaurent A.M., Morel S., Lockman L., et al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol 2009, 183:6186-6197.
93. Klinman D.M., CpG D.N.A. as a vaccine adjuvant. Expert Rev Vaccines 2003, 2:305-315.
94. Klinman D.M., Currie D., Gursel I., et al. Use of CpG oligodeoxynucleotides as immune adjuvants. Immunol Rev 2004, 199:201-216.
95. Krieg A.M., Matson S., Fisher E. Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. Antisense Nucleic Acid Drug Dev 1996, 6:133-139.
96. Roda J.M., Parihar R., Carson W.E. CpG-containing oligodeoxynucleotides act through TLR9 to enhance the NK cell cytokine response to antibody-coated tumor cells. J Immunol 2005, 175:1619-1627.
97. Weeratna R.D., McCluskie M.J., Xu Y., et al. CpG DNA induces stronger immune responses with less toxicity than other adjuvants. Vaccine 2000, 18:1755-1762.
98. McCluskie M.J., Davis H.L. CpG DNA as mucosal adjuvant. Vaccine 1999, 18:231-237.
99. Ellis R.D., Martin L.B., Shaffer D., et al. Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One 2010, 5:e8787. doi:10.1371/journal.pone.0008787.
100. Ellis R.D., Mullen G.E., Pierce M., et al. A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine 2009, 27:4104-4109.
101. Sogaard O.S., Lohse N., Harboe Z.B., et al. Improving the immunogenicity of pneumococcal conjugate vaccine in HIV-infected adults with a Toll-like receptor 9 agonist adjuvant: a randomized, controlled trial. Clin Infect Dis 2010, 51:42-50.
102. Cooper C.L., Davis H.L., Angel J.B., et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005, 19:1473-1479.
103. Sablan B.P., Kim D.J., Barzaga N.G., et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. Vaccine 2012, 30:2689.
104. Cooper C.L., Davis H.L., Morris M.L., et al. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol 2004, 24:693-701.
105. Schellack C., Prinz K., Egyed A., et al. IC31, a novel adjuvant signaling via TLR9, induces potent cellular and humoral immune responses. Vaccine 2006, 24:5461-5472.
106. van Dissel J.T., Arend S.M., Prins C., et al. Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naive human volunteers. Vaccine 2010, 28:3571-3581.
107. Lingnau K., Riedl K., von G.A. IC31 and IC30, novel types of vaccine adjuvant based on peptide delivery systems. Expert Rev Vaccines 2007, 6:741-746.
108. Turley C.B., Rupp R.E., Johnson C., et al. Safety and immunogenicity of a recombinant M2e-flagellin influenza vaccine (STF2.4xM2e) in healthy adults. Vaccine 2011, 29:5145-5152.
109. Taylor D.N., Treanor J.J., Strout C., et al. Induction of a potent immune response in the elderly using the TLR-5 agonist, flagellin, with a recombinant hemagglutinin influenza-flagellin fusion vaccine (VAX125, STF2.HA1 SI). Vaccine 2011, 29:4897-4902.
110. Talbot H.K., Rock M.T., Johnson C., et al. Immunopotentiation of trivalent influenza vaccine when given with VAX102, a recombinant influenza M2e vaccine fused to the TLR5 ligand flagellin. PLoS One 2010, 5:e14442.
111. Tomai M.A., Vasilakos J.P. TLR-7 and -8 agonists as vaccine adjuvants. Expert Rev Vaccines 2011, 10:405-407.
112. Burns R.P., Ferbel B., Tomai M., et al. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol 2000, 94:13-23.
113. Heil F., Ahmad-Nejad P., Hemmi H., et al. The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. Eur J Immunol 2003, 33:2987-2997.
114. Akira S., Hemmi H. Recognition of pathogen-associated molecular patterns by TLR family. Immunol Lett 2003, 85:85-95.
115. Roukens A.H., Vossen A.C., Boland G.J., et al. Intradermal hepatitis B vaccination in non-responders after topical application of imiquimod (Aldara). Vaccine 2010, 28:4288-4293.
116. Othoro C., Johnston D., Lee R., et al. Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect Immun 2009, 77:739-748.
117. Adams S., O'Neill D.W., Nonaka D., et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008, 181:776-784.
118. Sanders M.T., Brown L.E., Deliyannis G., et al. ISCOM-based vaccines: the second decade. Immunol Cell Biol 2005, 83:119-128.
119. Sjolander A., Cox J.C., Barr I.G. ISCOMs: an adjuvant with multiple functions. J Leukoc Biol 1998, 64:713-723.
120. Lovgren B.K., Morein B., Osterhaus A.D. ISCOM technology-based matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines 2011, 10:401-403.
121. Sun H.X., Xie Y., Ye Y.P. ISCOMs and ISCOMATRIX. Vaccine 2009, 27:4388-4401.
122. McKenzie A., Watt M., Gittleson C. ISCOMATRIX vaccines: safety in human clinical studies. Hum Vaccin 2010, 6:237-246. doi.org/10.4161/hv.6.3.10754.
123. Kensil C.R., Soltysik S., Wheeler D.A., et al. Structure/function studies on QS-21, a unique immunological adjuvant from Quillaja saponaria. Adv Exp Med Biol 1996, 404:165-172.
124. Garçon N., Chomez P., Van Mechelen M. A GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6:723-739.
125. Ansong D., Asante K.P., Vekemans J., et al. T cell responses to the RTS,S/AS01(E) and RTS,S/AS02(D) malaria candidate vaccines administered according to different schedules to Ghanaian children. PLoS One 2011, 6:e18891.
126. Lell B., Agnandji S., von Glasenapp I., et al. A randomized trial assessing the safety and immunogenicity of AS01 and AS02 adjuvanted RTS,S malaria vaccine candidates in children in Gabon. PLoS One 2009, 4:e7611. doi:10.1371/journal.pone.0007611.
127. Cohen J., Benns S., Vekemans J., et al. The malaria vaccine candidate RTS,S/AS is in phase III clinical trials [in French]. Ann Pharm Fr 2010, 68:370-379.
128. Sabbatini P.J., Ragupathi G., Hood C., et al. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer. Clin Cancer Res 2007, 13:4170-4177.
129. Soltysik S., Wu J.Y., Recchia J., et al. Structure/function studies of QS-21 adjuvant: assessment of triterpene aldehyde and glucuronic acid roles in adjuvant function. Vaccine 1995, 13:1403-1410.
130. Ragupathi G., Gardner J.R., Livingston P.O., et al. Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer. Expert Rev Vaccines 2011, 10:463-470.
131. Adams M.M., Damani P., Perl N.R., et al. Design and synthesis of potent Quillaja saponin vaccine adjuvants. J Am Chem Soc 2010, 132:1939-1945.
132. Moser C., Amacker M., Zurbriggen R. Influenza virosomes as a vaccine adjuvant and carrier system. Expert Rev Vaccines 2011, 10:437-446.
133. El'shina G.A., Gorbunov M.A., Shervarli V.I., et al. Evaluation of the effectiveness of influenza trivalent polymer subunit vaccine Grippol [in Russian]. Zh Mikrobiol Epidemiol Immunobiol 1998, 3:40-43.
134. Dyakonova V.A., Dambaeva S.V., Pinegin B.V., et al. Study of interaction between the polyoxidonium immunomodulator and the human immune system cells. Int Immunopharmacol 2004, 4:1615-1623.
135. Andrianov A.K., Decollibus D.P., Gillis H.A., et al. Poly[di(carboxylatophenoxy)phosphazene] is a potent adjuvant for intradermal immunization. Proc Natl Acad Sci U S A 2009, 106:18936-18941.
136. Payne L.G., Jenkins S.A., Andrianov A., et al. Water-soluble phosphazene polymers for parenteral and mucosal vaccine delivery. Pharm Biotechnol 1995, 6:473-493.
137. Luhrs P., Schmidt W., Kutil R., et al. Induction of specific immune responses by polycation-based vaccines. J Immunol 2002, 169:5217-5226.
138. Ghendon Y., Markushin S., Akopova I., et al. Chitosan as an adjuvant for poliovaccine. J Med Virol 2011, 83:847-852.
139. Ghendon Y., Markushin S., Krivtsov G., et al. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines. Arch Virol 2008, 153:831-837.
140. Guy B., Pascal N., Francon A., et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 2001, 19:1794-1805.
141. Agger E.M., Rosenkrands I., Hansen J., et al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008, 3:e3116. doi:10.1371/journal.pone.0003116.
142. Christensen D., Agger E.M., Andreasen L.V., et al. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J Liposome Res 2009, 19:2-11.
143. Pizza M., Giuliani M.M., Fontana M.R., et al. Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants. Vaccine 2001, 19:2534-2541.
144. da Hora V.P., Conceicao F.R., Dellagostin O.A., et al. Non-toxic derivatives of LT as potent adjuvants. Vaccine 2011, 29:1538-1544.
145. Norton E.B., Lawson L.B., Freytag L.C., et al. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 2011, 18:546-551.
146. Pizza M., Giuliani M.M., Fontana M.R., et al. LTK63 and LTR72, two mucosal adjuvants ready for clinical trials. Int J Med Microbiol 2000, 290:455-461.
147. Stephenson I., Zambon M.C., Rudin A., et al. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006, 80:4962-4970.
148. Mutsch M., Zhou W., Rhodes P., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350:896-903.
149. Lewis D.J., Huo Z., Barnett S., et al. Transient facial nerve paralysis (Bell's palsy) following intranasal delivery of a genetically detoxified mutant of Escherichia coli heat labile toxin. PLoS One 2009, 4:e6999. doi:10.1371/journal.pone.0006999.
150. Cunningham K.A., Carey A.J., Lycke N., et al. CTA1-DD is an effective adjuvant for targeting anti-chlamydial immunity to the murine genital mucosa. J Reprod Immunol 2009, 81:34-38.
151. Sundling C., Schon K., Morner A., et al. CTA1-DD adjuvant promotes strong immunity against human immunodeficiency virus type 1 envelope glycoproteins following mucosal immunization. J Gen Virol 2008, 89(pt 12):2954-2964.
152. Garçon N., Segal L., Tavares F., et al. The safety evaluation of adjuvants during vaccine development: the AS04 experience. Vaccine 2011, 29:4453-4459.